Total Payments
$58,981
2024 Payments
$5,627
Companies
13
Transactions
108
Payment Breakdown by Category
Other$47,565 (80.6%)
Travel$6,930 (11.8%)
Food & Beverage$2,337 (4.0%)
Research$1,423 (2.4%)
Consulting$675.00 (1.1%)
Education$49.98 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $46,415 | 12 | 78.7% |
| Travel and Lodging | $6,930 | 20 | 11.8% |
| Food and Beverage | $2,337 | 50 | 4.0% |
| Unspecified | $1,423 | 12 | 2.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,150 | 2 | 1.9% |
| Consulting Fee | $675.00 | 1 | 1.1% |
| Education | $49.98 | 11 | 0.1% |
Payments by Type
General
$57,557
96 transactions
Research
$1,423
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Pharma plc | $25,969 | 24 | $0 (2018) |
| Horizon Therapeutics plc | $24,257 | 28 | $0 (2023) |
| Chiesi USA, Inc. | $4,195 | 3 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $1,664 | 14 | $0 (2019) |
| SANOFI US SERVICES INC. | $1,423 | 12 | $0 (2024) |
| Cycle Pharmaceuticals Inc | $858.65 | 2 | $0 (2024) |
| GENZYME CORPORATION | $341.90 | 9 | $0 (2023) |
| Shire North American Group Inc | $99.86 | 2 | $0 (2019) |
| Retrophin, Inc. | $76.36 | 7 | $0 (2019) |
| Rhythm Pharmaceuticals, Inc. | $31.91 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,627 | 16 | Chiesi USA, Inc. ($4,195) |
| 2023 | $13,296 | 18 | Horizon Therapeutics plc ($12,190) |
| 2022 | $8,470 | 12 | Horizon Therapeutics plc ($8,447) |
| 2021 | $975.00 | 1 | Horizon Therapeutics plc ($975.00) |
| 2020 | $30.02 | 5 | GENZYME CORPORATION ($18.88) |
| 2019 | $4,160 | 22 | Horizon Therapeutics plc ($2,646) |
| 2018 | $11,645 | 20 | Horizon Pharma plc ($11,433) |
| 2017 | $14,778 | 14 | Horizon Pharma plc ($14,536) |
All Payment Transactions
108 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2024 | Cycle Pharmaceuticals Inc | Javygtor (Drug) | Food and Beverage | In-kind items and services | $8.65 | General |
| Category: PKU | ||||||
| 07/18/2024 | Chiesi USA, Inc. | LAMZEDE (Drug) | Honoraria | Cash or cash equivalent | $3,600.00 | General |
| Category: ERT FOR ALPHA-MANNOSIDOSIS | ||||||
| 07/18/2024 | Chiesi USA, Inc. | LAMZEDE (Drug) | Travel and Lodging | Cash or cash equivalent | $574.96 | General |
| Category: ERT FOR ALPHA-MANNOSIDOSIS | ||||||
| 07/18/2024 | Chiesi USA, Inc. | LAMZEDE (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: ERT FOR ALPHA-MANNOSIDOSIS | ||||||
| 07/02/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $34.57 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 07/02/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $34.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 07/02/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $26.80 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $439.15 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $296.97 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $213.57 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $77.66 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $62.71 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $36.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $28.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/12/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $28.00 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 06/11/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $145.66 | Research |
| Study: DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | ||||||
| 12/14/2023 | Ultragenyx Pharmaceutical Inc. | DOJOLVI (Drug) | Education | In-kind items and services | $30.00 | General |
| Category: Oral nutritional supplements | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $5,600.00 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $531.80 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $175.00 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $148.35 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $54.99 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $46.65 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $23.80 | General |
| Category: RAVICTI | ||||||
| 10/27/2023 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $23.80 | General |
| Category: RAVICTI | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DFI-Phase 1/2 Dose ESC & EXP Study of SAR444836 (gene therapy) in Pts. w/Phenlyketonuria | SANOFI US SERVICES INC. | $1,423 | 12 |
About Dr. Neena Champaigne, M.D
Dr. Neena Champaigne, M.D is a Pediatrics healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972554897.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neena Champaigne, M.D has received a total of $58,981 in payments from pharmaceutical and medical device companies, with $5,627 received in 2024. These payments were reported across 108 transactions from 13 companies. The most common payment nature is "Honoraria" ($46,415).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Clinical Genetics (M.D.)
- Location Charleston, SC
- Active Since 05/15/2006
- Last Updated 11/30/2020
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1972554897
Products in Payments
- RAVICTI (Drug) $49,999
- LAMZEDE (Drug) $4,195
- Palynziq (Drug) $1,395
- NITYR (Drug) $850.00
- Kuvan (Drug) $268.86
- NO_PRODUCT (Drug) $119.11
- FABRAZYME (Biological) $105.05
- NEXVIAZYME (Biological) $100.24
- DISEASE STATE (Drug) $89.45
- DOJOLVI (Drug) $30.00
- VPRIV (Biological) $22.37
- (820) Cholbam (Drug) $19.98
- XLSD (Drug) $15.71
- FABRY-DISEASE (Drug) $11.74
- Javygtor (Drug) $8.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Charleston
Lara Wine Lee, M.d, M.D
Pediatrics — Payments: $141,439
Pediatrics $141,439
Dr. Allison Eckard, Md, MD
Pediatrics — Payments: $37,829
Pediatrics $37,829
Dr. Stephen Stripling, M.d, M.D
Pediatrics — Payments: $29,486
Pediatrics $29,486
Melissa Henshaw, Md, MD
Pediatrics — Payments: $16,700
Pediatrics $16,700
Dr. Letitia Tierney, Md, MD
Pediatrics — Payments: $14,513
Pediatrics $14,513
Dr. Robert Clifford, M.d, M.D
Pediatrics — Payments: $12,494
Pediatrics $12,494